Alnylam Pharmaceuticals
(ALNY)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 127,328 | -123,756 | -57,479 | -278,157 | -194,394 |
| Depreciation Amortization | 42,152 | 28,349 | 14,405 | 56,670 | 42,502 |
| Income taxes - deferred | 24,972 | 19,374 | 9,639 | -106,762 | 631 |
| Accounts receivable | -544,210 | -144,347 | -7,434 | -86,550 | -27,042 |
| Accounts payable and accrued liabilities | 249,920 | 26,411 | -155,737 | 91,093 | 153,200 |
| Other Working Capital | -371,629 | -166,969 | -217,046 | -214,084 | -105,789 |
| Other Operating Activity | 831,992 | 396,354 | 295,338 | 529,478 | 217,242 |
| Operating Cash Flow | $360,525 | $35,416 | $-118,314 | $-8,312 | $86,350 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 511,050 | -4,349 | 122,739 | -63,246 | -19,547 |
| PPE Investments | -35,405 | -23,263 | -8,970 | -34,277 | -25,183 |
| Purchase Of Investment | 0 | 0 | 0 | -19,200 | -19,200 |
| Other Investing Activity | -2,150 | 0 | 0 | -117 | 0 |
| Investing Cash Flow | $473,495 | $-27,612 | $113,769 | $-116,840 | $-63,930 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 608,647 | N/A | N/A | N/A | N/A |
| Debt Repayment | -1,102,659 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 208,327 | 130,587 | 49,365 | 302,951 | 266,673 |
| Other Financing Activity | -64,822 | -32,746 | -5,281 | -8,792 | -3,511 |
| Financing Cash Flow | $-350,507 | $97,841 | $44,084 | $294,159 | $263,162 |
| Exchange Rate Effect | 40,637 | 41,564 | 14,058 | -15,239 | 2,032 |
| Beginning Cash Position | 968,652 | 968,652 | 968,652 | 814,884 | 814,884 |
| End Cash Position | 1,492,802 | 1,115,861 | 1,022,249 | 968,652 | 1,102,498 |
| Net Cash Flow | $524,150 | $147,209 | $53,597 | $153,768 | $287,614 |
| Free Cash Flow | |||||
| Operating Cash Flow | 360,525 | 35,416 | -118,314 | -8,312 | 86,350 |
| Capital Expenditure | -35,405 | -23,263 | -8,970 | -34,277 | -25,183 |
| Free Cash Flow | 325,120 | 12,153 | -127,284 | -42,589 | 61,167 |